The present study represents the first direct confirmation that celecoxib is efficacious in lipogenesis‐related NAFLD by suppressing the Akt‐dependent enhancement of hepatic de novo lipogenesis. This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatotic liver disease.